These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36932396)

  • 1. Association of neutrophil-lymphocyte ratio with survival in peripheral early-stage non-small cell lung cancer after stereotactic body radiation therapy.
    Huang K; Prasad S; Ma SJ; Yu H; Iovoli AJ; Farrugia MK; Dexter EU; Demmy TL; Malik NK; Singh AK
    BMC Cancer; 2023 Mar; 23(1):254. PubMed ID: 36932396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Pre-Treatment NLR and Other Hematologic Biomarkers on the Outcomes of Early-Stage Non-Small-Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy.
    Aduquaye M; Dube S; Bashir B; Chowdhury A; Ahmed N; Leylek A; Kim J; Lambert P; Bucher O; Hunter W; Sivananthan G; Koul R; Rathod S
    Curr Oncol; 2022 Jan; 29(1):193-208. PubMed ID: 35049693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-treatment neutrophil-lymphocyte ratio is associated with overall mortality in localized non-small cell lung cancer treated with stereotactic body radiotherapy.
    Sebastian N; Wu T; Bazan J; Driscoll E; Willers H; Yegya-Raman N; Bond L; Dwivedi A; Mo X; Tan Y; Xu-Welliver M; Haglund K; Jabbour SK; Keane FK; Williams TM
    Radiother Oncol; 2019 May; 134():151-157. PubMed ID: 31005209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer.
    Cannon NA; Meyer J; Iyengar P; Ahn C; Westover KD; Choy H; Timmerman R
    J Thorac Oncol; 2015 Feb; 10(2):280-5. PubMed ID: 25299234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
    Shaverdian N; Veruttipong D; Wang J; Schaue D; Kupelian P; Lee P
    Clin Lung Cancer; 2016 Jan; 17(1):39-46. PubMed ID: 26372098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR) in locally advanced non-small cell lung cancer patients treated with thoracic radiation].
    Dong X; Zhou ZM; Bi N; Wang JB; Ran JT; Hui ZG; Liang J; Feng QF; Chen DF; Xiao ZF; Lyu JM; Wang XZ; Wang X; Zhang T; Deng L; Wang WQ; Wang LH
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):446-451. PubMed ID: 29936771
    [No Abstract]   [Full Text] [Related]  

  • 7. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic utility of pretreatment neutrophil-lymphocyte ratio in survival outcomes in localized non-small cell lung cancer patients treated with stereotactic body radiotherapy: Selection of an ideal clinical cutoff point.
    Kotha NV; Cherry DR; Bryant AK; Nalawade V; Stewart TF; Rose BS
    Clin Transl Radiat Oncol; 2021 May; 28():133-140. PubMed ID: 33997320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutrophil-to-Lymphocyte Ratio Is Superior to Other Leukocyte-Based Ratios as a Prognostic Predictor in Non-Small Cell Lung Cancer Patients with Radiosurgically Treated Brain Metastases Under Immunotherapy or Targeted Therapy.
    Cho A; Kranawetter B; Untersteiner H; Khalaveh F; Dorfer C; Rössler K; Zöchbauer-Müller S; Gatterbauer B; Hochmair MJ; Frischer JM
    World Neurosurg; 2021 Jul; 151():e324-e331. PubMed ID: 33878466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value of prognostic nutritional index (PNI) and neutrophil to lymphocyte ratio (NLR) for advanced non-small cell lung cancer treated with platinum-based chemotherapeutics.
    Wang J; Liu Y; Mi X; Shao M; Liu L
    Ann Palliat Med; 2020 May; 9(3):967-978. PubMed ID: 32389020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy.
    Scilla KA; Bentzen SM; Lam VK; Mohindra P; Nichols EM; Vyfhuis MA; Bhooshan N; Feigenberg SJ; Edelman MJ; Feliciano JL
    Oncologist; 2017 Jun; 22(6):737-742. PubMed ID: 28533476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic utility of blood inflammation biomarkers before and after treatment on the survival of patients with locally advanced non-small cell lung cancer undergoing stereotactic body radiotherapy.
    Fang F; Jia Z; Xie H; Cao Y; Zhu X; Yang XY; Guo X; Zhang H
    Clin Respir J; 2024 May; 18(5):e13749. PubMed ID: 38685745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Survival Outcomes of Single- and Five-Fraction Schedules of Stereotactic Body Radiation Therapy for Early-Stage Central or Peripheral NSCLC.
    Huang K; Prasad S; Ma SJ; Iovoli AJ; Farrugia MK; Malik NK; Singh AK
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
    Deng M; Ma X; Liang X; Zhu C; Wang M
    Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic Inflammatory Markers of Survival in Epidermal Growth Factor-Mutated Non-Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis.
    Chan SWS; Smith E; Aggarwal R; Balaratnam K; Chen R; Hueniken K; Fazelzad R; Weiss J; Jiang S; Shepherd FA; Bradbury PA; Sacher AG; Leighl NB; Xu W; Brown MC; Eng L; Liu G
    Clin Lung Cancer; 2021 Sep; 22(5):390-407. PubMed ID: 33582072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic implications of neutrophil-to-lymphocyte ratio in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy: A multicenter, real-world study.
    Bi H; Ren D; Xiao Y; Zhou Y; Yi B; Han W; Shao Y; Wang J; Zhang C; Wang H
    Thorac Cancer; 2024 Mar; 15(7):559-569. PubMed ID: 38294282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incorporation of the SUVmax Measured From FDG PET and Neutrophil-to-lymphocyte Ratio Improves Prediction of Clinical Outcomes in Patients With Locally Advanced Non-small-cell Lung Cancer.
    Guo D; Jin F; Jing W; Li M; Chen D; Zou B; Jiang G; Fu L; Zhu H; Kong L; Wu J; Yu J; Yue J
    Clin Lung Cancer; 2019 Nov; 20(6):412-419. PubMed ID: 31300364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic body radiation therapy versus conventionally fractionated radiation therapy for early stage non-small cell lung cancer.
    Haque W; Verma V; Polamraju P; Farach A; Butler EB; Teh BS
    Radiother Oncol; 2018 Nov; 129(2):264-269. PubMed ID: 30031630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of systemic inflammation biomarkers on overall survival after lung cancer radiotherapy: a single-center large-cohort study.
    Abravan A; Salem A; Price G; Faivre-Finn C; van Herk M
    Acta Oncol; 2022 Feb; 61(2):163-171. PubMed ID: 34979860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
    Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
    Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.